Raab & Moskowitz Asset Management LLC cut its position in UnitedHealth Group Incorporated (NYSE:UNH) by 0.7% in the first quarter, HoldingsChannel.com reports. The firm owned 7,364 shares of the healthcare conglomerate’s stock after selling 53 shares during the period. Raab & Moskowitz Asset Management LLC’s holdings in UnitedHealth Group were worth $2,739,000 as of its most recent SEC filing.
Several other hedge funds have also modified their holdings of UNH. Norges Bank purchased a new stake in shares of UnitedHealth Group during the fourth quarter worth about $3,397,896,000. Viking Global Investors LP purchased a new stake in shares of UnitedHealth Group during the fourth quarter worth about $979,682,000. Price T Rowe Associates Inc. MD grew its stake in shares of UnitedHealth Group by 5.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 38,003,233 shares of the healthcare conglomerate’s stock worth $13,318,678,000 after acquiring an additional 1,881,407 shares during the last quarter. Morgan Stanley grew its stake in shares of UnitedHealth Group by 14.1% during the fourth quarter. Morgan Stanley now owns 7,989,764 shares of the healthcare conglomerate’s stock worth $2,801,850,000 after acquiring an additional 986,472 shares during the last quarter. Finally, Alliancebernstein L.P. boosted its position in UnitedHealth Group by 5.2% in the fourth quarter. Alliancebernstein L.P. now owns 11,485,225 shares of the healthcare conglomerate’s stock valued at $4,027,639,000 after buying an additional 569,142 shares during the last quarter. Institutional investors and hedge funds own 86.03% of the company’s stock.
UNH stock traded up $0.84 during mid-day trading on Tuesday, reaching $406.74. The company had a trading volume of 27,315 shares, compared to its average volume of 3,262,127. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.82 and a current ratio of 0.82. The company has a market capitalization of $383.92 billion, a price-to-earnings ratio of 23.31, a price-to-earnings-growth ratio of 1.55 and a beta of 0.74. The firm has a fifty day simple moving average of $378.48 and a 200 day simple moving average of $349.25. UnitedHealth Group Incorporated has a fifty-two week low of $273.71 and a fifty-two week high of $406.77.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 23rd. Stockholders of record on Monday, March 15th were given a dividend of $1.25 per share. This represents a $5.00 annualized dividend and a dividend yield of 1.23%. The ex-dividend date was Friday, March 12th. UnitedHealth Group’s dividend payout ratio (DPR) is presently 33.09%.
In related news, CAO Thomas E. Roos sold 5,301 shares of the firm’s stock in a transaction that occurred on Tuesday, April 27th. The stock was sold at an average price of $394.66, for a total transaction of $2,092,092.66. Following the transaction, the chief accounting officer now owns 58,589 shares in the company, valued at approximately $23,122,734.74. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Richard T. Burke sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, April 19th. The stock was sold at an average price of $391.25, for a total value of $978,125.00. Following the transaction, the director now owns 154,181 shares in the company, valued at approximately $60,323,316.25. The disclosure for this sale can be found here. Insiders have sold a total of 20,420 shares of company stock worth $7,532,962 in the last 90 days. 0.80% of the stock is currently owned by company insiders.
A number of equities research analysts recently commented on the company. Credit Suisse Group upped their target price on UnitedHealth Group from $415.00 to $430.00 and gave the company an “outperform” rating in a research report on Thursday, April 22nd. Deutsche Bank Aktiengesellschaft boosted their price target on UnitedHealth Group from $409.00 to $418.00 and gave the company a “buy” rating in a report on Thursday, April 22nd. Mizuho boosted their price target on UnitedHealth Group from $380.00 to $394.00 and gave the company a “buy” rating in a report on Thursday, April 15th. Truist upped their target price on UnitedHealth Group from $420.00 to $450.00 in a research note on Wednesday, April 14th. Finally, BMO Capital Markets upped their target price on UnitedHealth Group from $410.00 to $435.00 and gave the stock a “market perform” rating in a research note on Thursday, April 22nd. Three equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $409.61.
About UnitedHealth Group
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance program, and health care programs; medical and dental benefits; and hospital and clinical services.
Want to see what other hedge funds are holding UNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UnitedHealth Group Incorporated (NYSE:UNH).
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.